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Staphylococcus aureus strains producing Panton-Valentine leukocidin (PVL) have been epidemiologically
linked to specific human infections. To evaluate immunological tests that may be used to diagnose
infections with PVL-producing strains, we prospectively collected pus, respiratory tract specimens, and
joint fluid specimens from which S. aureus had been isolated in clinical laboratories in six countries. An
enzyme-linked immunosorbent assay (ELISA) and an immunochromatographic test (ICT) targeting
LukS-PV were performed directly with clinical samples for the detection of PVL. The same tests were
applied to S. aureus culture supernatants. The corresponding S. aureus isolates were characterized by PCR
for the presence of the PVL locus (lukS-PV and lukF-PV) and the mecA gene. A total of 185 samples from
144 skin infections, 23 bone and joint infections, and 18 lower respiratory tract infections were analyzed.
By PCR, 72/185 S. aureus isolates were PVL locus positive (PVL); 28 of these were also mecA positive. PVL
was detected in the supernatants of all PVL strains by both ELISA and an ICT, while no signal was
observed with PVL-negative strains. The PVL concentrations in human clinical samples that grew PVL
strains ranged from 0 to 399 g/ml by ELISA. By the use of 0.015 g/ml of PVL as a cutoff value, PVL was
detected in 65/72 (90%) of the clinical samples by ELISA. The sensitivity and specificity of the ELISA test
were 90% and 100%, respectively. By the ICT, PVL was detected in 57/72 (79%) of the samples, and the
sensitivity and specificity of ICT were 79% and 100%, respectively. PVL is expressed by S. aureus during
human infection, and a PVL-specific ELISA and ICT could be reliable tests for the diagnosis of infections
caused by PVL-producing strains.
Staphylococcus aureus is an important human pathogen
whose pathogenicity largely depends on extracellular virulence
factors. One of these exoproteins, Panton-Valentine leukoci-
din (PVL), is produced by several community-acquired methi-
cillin-resistant S. aureus and methicillin-sensitive S. aureus
(CA-MRSA and CA-MSSA, respectively) clones currently
spreading throughout the world (27).
Historical publications show that PVL targets cells of the
human immune system, such as polymorphonuclear neutro-
phils (PMNs), monocytes, and macrophages (26). In vitro, PVL
forms pores on human and rabbit PMNs and monocytes that
cause cytokine release and cell death by apoptosis or necrosis
(13, 18). In rabbit models, PVL provokes a dose-dependent
skin necrosis (7, 30); bacterial persistence in bone; and a rapid
local extension of osteomyelitis (6), severe lung necrosis, pul-
monary edema, alveolar hemorrhage, and death (10).
Isolates of S. aureus harboring PVL genes have been epide-
miologically linked to specific human S. aureus manifestations:
not only to primary skin and soft tissue disease but also to
severe necrotizing pneumonia and severe bone and joint in-
fections (4, 11, 14, 19, 21, 24). In certain countries, such as the
United Kingdom and France, PVL is now detected in clinical
practice, and treatment regimens may be adjusted on the basis
of the presence or the absence of PVL (12, 15, 17). The ad-
junctive use of antibiotics that suppress toxin production, such
as clindamycin, linezolid, and rifampin, and intravenous immu-
noglobulin is advocated for the treatment of severe and inva-
sive infections caused by PVL-producing strains.
To date, the diagnosis of infection due to PVL-producing
strains is mainly performed by PCR of colonies for the detec-
tion of PVL genes, while the latex agglutination assay and
matrix-assisted laser desorption ionization–time of flight mass
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spectrometry method should be performed with colonies (3,
19, 23). However, the results of these methods of PVL detec-
tion may not correlate with in vivo production.
In a previous study, we have shown that PVL can be de-
tected in pus from a skin abscess caused mainly by PVL-
producing methicillin-susceptible S. aureus (1). The objective
of this study was to determine whether the PVL produced in
clinical specimens from PVL gene-positive S. aureus infections
could be detected by a specific enzyme-linked immunosorbent
assay (ELISA) or immunochromatographic test (ICT), regard-
less of the genetic background and methicillin susceptibility of
the PVL-producing strains.
(This work was presented at the 49th Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy, San Fran-
cisco, CA, 12 to 15 September 2009.)
MATERIALS AND METHODS
Sample inclusion. The study was conducted in accordance with the guidelines
of the ethical committees of the six participating hospitals. In each hospital,
specimens from human infections that were collected as part of the routine
management of patients with S. aureus infections were prospectively stored at
20°C in Eppendorf tubes over a period of 6 months. Only clinical specimens
with a volume of 300 l or greater were retained. Samples were shipped to Lyon,
France, on dry ice for PVL detection.
In total, 144 pus samples from S. aureus skin infections were obtained and
analyzed: 88 from France, 16 from Australia, 13 from Algeria, 10 from Singa-
pore, 10 from the United States, and 7 from Greece. In Lyon, France, we
collected an additional 18 clinical specimens from patients with pneumonia (4
pleural fluid, 3 bronchoalveolar lavage [BAL], 8 tracheal aspirate, and 3 sputum
specimens) and 23 specimens from patients with bone and joint infections (14
pus specimens from patients with osteitis and 9 joint fluid specimens).
Isolate analysis. S. aureus was identified on the basis of the colony and cell
morphologies, the results of coagulase testing with rabbit plasma (bioMe´rieux,
Marcy l’Etoile, France), and the results of tests with the Slidex Staph Plus kit
(bioMe´rieux). Genomic DNA was extracted from the staphylococcal cultures by
a standard procedure (20) and was used as the template for amplification by
using primers previously shown to be specific for the PVL genes (lukS-PV and
lukF-PV, which form the operon for the PVL locus) and the mecA gene (which
codes for methicillin resistance) (19, 22). Multilocus sequence types (STs) and
spa types were determined for PVL locus-positive (PVL) isolates, as described
previously (27).
Since the optimal yield of PVL is obtained by cultivation of strains in casein-
casein-yeast extract (CCY) broth, (3% [wt/vol] yeast extract, 2% Bacto Casamino
Acids, 2% sodium pyruvate, 0.25% NaHPO4, and 0.042% KH2PO4 [pH 7.0]), 5
ml of CCY medium was inoculated with each isolate (five colonies from an
overnight culture on blood agar) and incubated at 37°C with vigorous shaking for
18 h (31). After centrifugation, the culture supernatants were sterilized by 1 h of
heating at 94°C, followed by cooling at 4°C on ice for 5 min and storage at
4°C until PVL detection was performed.
Analysis of clinical specimens. All clinical specimens culture positive for S.
aureus (regardless of the luk-PV or mecA status of the corresponding isolates)
were thawed to4°C, vortexed for 1 min, sterilized by 1 h of heating at 94°C and
then cooling at 4°C on ice for 5 min, and centrifuged at 10,000  g for 5 min.
The supernatants were used for PVL detection and quantification.
PVL ELISA. PVL detection and quantification were performed by an anti-
body-sandwich ELISA targeting LukS-PV with solid-phase mouse anti-LukS-PV
monoclonal antibody and revelation by horseradish peroxidase-conjugated rabbit
polyclonal F(ab)2 anti-LukS-PV from the R&D Immunoassays department of
bioMe´rieux, as described by Badiou et al. with few modifications (1). Briefly, the
wells of microtiter plates (Sigma, Saint Quentin Fallavier, France) were coated
with anti-LukS-PV monoclonal antibody in phosphate-buffered saline (PBS)
overnight at room temperature. Unbound monoclonal antibody was washed out
twice with a solution of PBS-Tween (0.05%) (PBST), and nonspecific binding
sites were blocked with a PBST-milk (5%) solution for 30 min at 37°C. The plates
were further washed another tree times with PBST before standard recombinant
LukS-PV dilutions (from 0.005 to 0.8 g/ml in PBST-milk [1%]) or samples
(undiluted or diluted in PBST-milk [1%]) were added to duplicate wells for 1 h
30 min at 37°C (2). After three washes with PBST, horseradish peroxidase-
conjugated rabbit polyclonal F(ab)2 anti-LukS-PV was added. Subsequently, the
microplates were incubated for 1 h 30 min at 37°C and washed tree times with
PBST, before revelation by adding the enzyme substrate (tetramethylbenzidine).
After a 30-min incubation in the dark at room temperature, the reaction was
stopped by adding H2SO4 solution. The plates were read at 450 nm in a model
680 microplate reader (Bio-Rad). No signal was detected with recombinant
LukF-PV, HlgA, HlgB, HlgC, LukE, or LukD.
ICT. The ICT device was developed by the R&D Immunoassays department
of bioMe´rieux. It consisted of a chromatography strip, a separator, and an
absorbent pad, all housed in a cassette. The cassette contains a nitrocellulose
membrane on which monoclonal mouse anti-LukS-PV antibody is adsorbed. A
second mouse anti-LukS-PV antibody is coupled to red-dyed polystyrene micro-
spheres, which are dried onto an inert fibrous support. The test was per-
formed according to the instructions of the R&D Immunoassays department
of bioMe´rieux. Briefly, 70 l of sample was applied to the sample well of the
strip, and the sample migrated by capillary action along the nitrocellulose mem-
brane. If the sample contains LukS-PV, the LukS-PV present in the sample binds
to the anti-LukS-PV-conjugated antibodies and the resulting antigen-antibody
complexes are captured by the immobilized monoclonal mouse anti-LukS-PV
antibody, forming the test line. The test was read at 30 min, and the result was
interpreted by noting the presence or the absence of a visually detectable red
line. A positive test result was indicated by the detection of a red line in the test
line region. A negative test result was indicated by the absence of the red line.
Statistical analysis. The Mann-Whitney U test (because of the rejection of
normality) and receiver-operator-characteristic (ROC) curve analyses were per-
formed with SPSS software, version 16.0 (SPSS Inc., Chicago, IL), and were used
to identify differences in PVL titers between groups of strains or samples that
were PVL and PVL negative (PVL). The level of statistical significance was
set at a P value of 0.05.
RESULTS
Isolates analysis. One hundred eighty-five S. aureus isolates
recovered from patients with infections were analyzed for the
presence of the PVL locus and mecA genes by PCR (Table 1).
Seventy-two (39%) were positive for the PVL locus. mecA was
detected in 40 (22%) of the isolates; 12/40 (30%) isolates were
PVL and 28/40 (70%) were PVL. All PVL S. aureus iso-
lates were analyzed by multilocus sequence typing (MLST),
and their spa types were determined. The 72 PVL isolates
belonged to 20 different STs, corresponding to 36 different spa
types (Table 1).
Extracellular PVL production was evaluated by analyzing
the supernatants for all 185 isolates. By ICT, PVL was detected
in all 72 supernatants derived from the PVL isolates, while no
signal was observed with the 113 supernatants from the PVL
strains.
The quantity of PVL produced in vitro was determined by
ELISA. The level of PVL in the supernatants varied among
isolates, ranging from 0.09 to 14.57 g/ml (median, 1.28 g/
ml). There was no difference in the levels of PVL production in
vitro between mecA-positive (mecA) and mecA-negative
(mecA) isolates (for the mecA isolates the median was 1.17
g/ml and the range was 0.24 to 14.57 g/ml, and for the
mecA the median was 1.69 g/ml and the range was 0.09 to
14.40 g/ml; P  0.33). In order to examine whether isolates
belonging to specific STs were higher-level PVL producers, the
STs with nine and more isolates, i.e., strains belonging to ST8,
ST30, ST80, or ST121, were compared (Fig. 1). The PVL levels
in the supernatants of ST8 isolates (median, 5.05 g/ml; range,
3.56 to 14.57 g/ml) were similar to the PVL levels in the
supernatants of ST121 isolates (median, 7.98 g/ml; range,
0.26 to 14.30 g/ml) (P  0.81), but the PVL levels in the
supernatants of both ST8 and ST121 isolates were higher than
those in the supernatants of ST80 isolates (median, 0.75 g/ml;
range, 0.09 to 3.55 g/ml; P  0.007 and 0.003, respectively)
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and ST30 isolates (median, 0.44 g/ml; range, 0.10 to 14.40
g/ml; P  0.005 and P  0.003, respectively). The PVL levels
in the supernatants of ST80 isolates and ST30 isolates were
similar (P  0.054).
Clinical specimen analysis. The clinical specimens pro-
spectively collected from patients with S. aureus infections
were blindly analyzed in the Lyon laboratory for the pres-
ence of PVL.
By ICT, PVL was detected in 57/72 S. aureus PVL speci-
mens (79%) (Tables 1 and 2). These samples were derived
from 53/64 (83%) pus samples from skin infections, 2/2 bone
abscess samples, and 2/6 pulmonary samples (Table 1). The
two positive pulmonary specimens corresponded to pleural
fluids, while the negative specimens comprised one pleural
fluid specimen, one BAL specimen, one sputum specimen, and
one tracheal aspirate specimen. All 113 S. aureus PVL spec-
TABLE 1. Clinical samples and isolates used in this study and PVL detection by specific ICT and ELISAa
Infection type
(no. of isolates)
No. of
isolates ST
spa
type PVL mecA
PVL production (no. positive/total no.)
Isolates Clinical specimens
ICT ELISA ICT ELISA
Skin infections (144) 1 1 t3688   1/1 1/1 1/1 1/1
1 1 t127   1/1 1/1 1/1 1/1
1 5 t311   1/1 1/1 1/1 1/1
2 8 t008   2/2 2/2 2/2 2/2
8 8 t008   8/8 8/8 5/8 5/8
1 15 t084   1/1 1/1 1/1 1/1
1 22 t005   1/1 1/1 0/1 1/1
1 25 t4844   1/1 1/1 1/1 1/1
2 26 t078   2/2 2/2 2/2 2/2
1 30 t019   1/1 1/1 1/1 1/1
2 30 t021   2/2 2/2 2/2 2/2
1 30 t090   1/1 1/1 1/1 1/1
1 30 t242   1/1 1/1 1/1 1/1
1 30 t318   1/1 1/1 0/1 1/1
1 30 t363   1/1 1/1 1/1 1/1
1 30 t605   1/1 1/1 1/1 1/1
1 80 t042   1/1 1/1 1/1 1/1
11 80 t044   11/11 11/11 8/11 10/11
3 80 t044   3/3 3/3 3/3 3/3
1 88 t729   1/1 1/1 1/1 1/1
1 88 t1598   1/1 1/1 1/1 1/1
1 88 t3155   1/1 1/1 1/1 1/1
1 88 t4333   1/1 1/1 1/1 1/1
2 93 t202   2/2 2/2 2/2 2/2
1 120 t3616   1/1 1/1 1/1 1/1
2 121 t314   2/2 2/2 2/2 2/2
1 121 t582   1/1 1/1 1/1 1/1
1 121 t645   1/1 1/1 1/1 1/1
3 121 t3616   3/3 3/3 2/3 2/3
1 121 t4333   1/1 1/1 1/1 1/1
1 152 t355   1/1 1/1 1/1 1/1
1 152 t5227   1/1 1/1 1/1 1/1
1 217 t4466   1/1 1/1 0/1 1/1
1 291 t1614   1/1 1/1 0/1 1/1
1 378 t3651   1/1 1/1 1/1 1/1
1 728 t160   1/1 1/1 1/1 1/1
1 772 t657   1/1 1/1 1/1 1/1
1 1301 t3666   1/1 1/1 1/1 1/1
5 ND ND   0/5 0/5 0/5 0/5
75 ND ND   0/75 0/75 0/75 0/75
Pneumonia (18) 1 30 t021   1/1 1/1 0/1 0/1
4 80 t044   4/4 4/4 2/4 3/4
1 121 t5228   1/1 1/1 0/1 1/1
4 ND ND   0/4 0/4 0/4 0/4
8 ND ND   0/8 0/8 0/8 0/8
Bone/joint infection (23) 1 30 t302   1/1 1/1 1/1 1/1
1 152 t355   1/1 1/1 1/1 1/1
3 ND ND   0/3 0/3 0/3 0/3
18 ND ND   0/18 0/18 0/18 0/18
a STs were determined by multilocus sequence typing. PVL locus genes, which encode the Panton-Valentine leukocidin, and the mecA gene, which codes for
methicillin resistance, were detected by PCR of the corresponding genes. The cutoff value for the PVL ELISA was 0.015 g/ml; , negative; , positive; ND, not
determined.
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imens were negative by ITC. Thus, for clinical specimens, the
sensitivity and the specificity of ICT were 79% and 100%,
respectively (Table 2).
By ELISA, the PVL concentrations in the 72 S. aureus PVL
samples had a median of 0.42 g/ml (range, 0 to 399 g/ml), as
shown in Fig. 2. The PVL concentrations had medians of 0.54
g/ml (range, 0 to 399 g/ml) in pus from skin infections, 0.11
g/ml (range, 0 to 0.33 g/ml) in pulmonary samples, and
128.4 g/ml (range, 0.10 to 256 g/ml) in bone abscess sam-
ples.
PVL was not detected by ELISA in seven human samples
harboring PVL strains. Those samples were also negative for
PVL by ICT. Eight S. aureus PVL samples negative for PVL
by ITC had detectable values by ELISA: median, 0.29 g/ml
(range, 0.021 to 1.049 g/ml). There was no difference in the
PVL levels in pus from skin infections related to whether the
corresponding PVL S. aureus infecting isolates were mecA
or mecA (P  0.40).
Likewise, the PVL levels in the skin abscess specimens were
not related to a certain genetic background (ST; i.e., ST8,
ST80, ST30, and ST121) (P value range, 0.07 to 0.68) (Fig. 2).
PVL was detected in only two samples that grew S. aureus
PVL strains; these were two pus samples from skin infections,
in which we detected 0.005 g/ml of PVL, which corresponds
to the detection limit of our ELISA. The area under the ROC
curves was 0.97 (95% confidence interval, 0.93 to 0.99; P 
0.001), and 0.015 g/ml was determined to be the cutoff value
for the ELISA. By use of this cutoff value, PVL was detected
in 65/72 (90%) of the S. aureus PVL clinical specimens. They
corresponded to 59/64 (92%) of the samples of pus from S.
aureus PVL skin infections (39/40 [98%] from France and
20/24 [83%] from other countries; P  0.038), 2/2 S. aureus
FIG. 1. Variability of PVL production among clinical isolates of S. aureus with a given genetic background. Isolates were grouped according
to their multilocus sequence type. ST8 MRSA strains correspond to the USA300 CA-MRSA clone, ST80 strains correspond to the European
CA-MRSA clone, and ST93 strains correspond to the Queensland ST93 CA-MRSA clone, while ST121 strains correspond to a predominant
methicillin-sensitive S. aureus PVL clone spreading in Europe (20, 25, 29). The level of PVL production in vitro was measured by ELISA. The
results are expressed as the means of three experiments  standard errors of the means. *, P  0.05, Mann-Whitney U test.
TABLE 2. Results obtained by ICT and ELISA with the clinical specimens
Test and isolate source
No. of isolates with the following result/total no. tested:
Sensitivity
(%)
Specificity
(%)True
positive
False
positive
True
negative
False
negative
ITC
Total 57/72 0/113 113/113 15/72 79 100
Skin infection 53/64 0/80 80/80 11/64 83 100
Pneumonia 2/6 0/12 12/12 4/6 NAa NA
Bone and joint infection 2/2 0/21 21/21 0/2 NA NA
ELISA
Total 65/72 0/113 113/113 7/72 90 100
Skin infection 59/64 0/80 80/80 5/64 92 100
Pneumonia 4/6 0/12 12/12 2/6 NA NA
Bone and joint infection 2/2 0/21 21/21 0/2 NA NA
a NA, not applicable due to the small number of corresponding samples.
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PVL bone abscess samples, and 4/6 (67%) of the pulmonary
samples from patients with S. aureus PVL pneumonia. The
sensitivity and the specificity of the ELISA were 90% and
100%, respectively (Table 2). The results observed by ELISA
and ICT were strongly correlated (P  0.001). When we com-
pared the PVL concentrations in clinical specimens to those
produced by the corresponding isolates in vitro, we did not find
a correlation (Pearson correlation test, P  0.20). However,
there were very good correlations between the presence of the
genes by PCR, in vivo production (of any concentration), and
in vitro production (P  0.001).
DISCUSSION
The aim of the study described here was to determine
whether the PVL produced in clinical specimens obtained
from patients with PVL gene-positive S. aureus infections
could be detected by a specific ELISA or ICT.
For this purpose, we prospectively collected and analyzed
clinical specimens and the corresponding S. aureus strains iso-
lated from patients with infections in which PVL was suspected
to play a role in the pathophysiology, i.e., skin infections, pneu-
monia, and bone and joint infections (4, 11, 14, 19, 24). Sam-
ples were collected from six different countries to obtain strains
with more diverse genetic backgrounds (27).
We collected 185 pairs of S. aureus strains and clinical spec-
imens. Thirty-nine percent of the strains carried the genes for
the PVL locus. All these strains produced PVL in vitro, while
no PVL was detected in the culture supernatants of PVL
strains. On the basis of these results, we concluded that the
sensitivities and the specificities of both the ICT and the
ELISA methods for the detection of PVL-producing strains
were equivalent to those of the PCR method. MLST and spa
typing analyses showed that the PVL strains were distributed
among 36 different clones. Some of the PVL strains belonged
to predominant CA-MRSA clones ST8 (the USA300 clone)
(25), ST80 (the European ST80 CA-MRSA clone), and ST93
(the Queensland ST93 CA-MRSA clone) (29). The levels of
PVL production in vitro varied between strains, even within
specific genetic backgrounds. This interstrain variability has
previously been reported for ST8 strains (16), and we also
report the same observation for other STs, such as ST80 and
FIG. 2. Variability of PVL concentration among clinical specimens containing S. aureus isolates with a given genetic background. Isolates were
grouped according to their multilocus sequence types, while the PVL concentrations in samples from which the corresponding strains were isolated
were measured by ELISA.
1388 BADIOU ET AL. J. CLIN. MICROBIOL.
 o
n
 O
ctober 21, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
ST93. We noted that certain STs were stronger PVL producers
in vitro: ST8 PVL strains corresponding to CA-MRSA clone
USA300 and ST121 PVL strains corresponding to a predom-
inant MSSA clone spreading in Europe (20) were the two
strongest PVL producers, while ST80 PVL strains (the Eu-
ropean CA-MRSA clone) produced 7-fold less PVL. The ori-
gin of the variation in PVL production is not known. Since
CA-MRSA frequently carries the PVL genes (29), we exam-
ined whether mecA strains produced more PVL than mecA
strains. However, no differences in the PVL concentrations
were observed between mecA and mecA strains either in the
global analysis or in the analysis restricted to STs. Therefore, it
seems unlikely that mecA has an impact on PVL production or
influences the fitness of strains by modulation of PVL expres-
sion. The association between the mecA and the PVL locus
genes in CA-MRSA remains to be elucidated.
Since all of the PVL strains produced PVL in vitro, we
expected that we would detect PVL in the corresponding spec-
imens. We detected PVL in the great majority of the clinical
samples using the two immunological methods (ICT and
ELISA). For ICT and ELISA, the sensitivities were 79% and
92%, respectively, while the specificities were 100% for both
methods. We did not detect PVL in clinical specimens that
grew PVL strains by ICT when the strains were PVL negative
by ELISA. ICT appeared to be slightly less sensitive than
ELISA. The difference in sensitivity between these two meth-
ods may be related to the use of different antibodies: two
monoclonal antibodies for ICT versus one monoclonal anti-
body and polyclonal antibodies for ELISA. When we examined
the results for the skin infection specimens, we noted that
isolates in which no PVL production was detected were statis-
tically more commonly from outside of Lyon. This suggests
that storage and transportation may have caused PVL deteri-
oration. Moreover, clinical specimens contain proteases pro-
duced by S. aureus and released by host cell alteration that may
damage the PVL if the sample is not rapidly examined. All
pulmonary specimens were collected in France. Only two re-
spiratory samples were PVL negative by ELISA. One of these
patients had necrotizing pneumonia and the blood culture
grew PVL S. aureus, while the pleural effusion, from which
our specimen was obtained, was culture negative. In the second
patient, the BAL fluid specimen tested grew PVL S. aureus at
a colony count of less than 104/ml. These two cases suggest that
PVL detection in clinical specimens by ELISA and ICT is
dependent on the presence of a sufficient density of PVL-
producing bacterial cells.
Using ELISA, we were able to quantify the level of PVL in
human samples with PVL isolates. The PVL concentrations
varied from 0 to 399 g/ml. Previous studies have reported that
a toxin concentration of 0.050 g/ml induces human polymor-
phonuclear leukocyte activation (18), one of 0.33 g/ml causes
human polymorphonuclear leukocyte apoptosis (13), and an
intradermal injection of 0.3 g causes local inflammation and
necrosis in a rabbit experimental model (7, 30). Ninety percent
of the PVL specimens contained PVL at concentrations toxic
for human leukocytes. Our results confirm the previous obser-
vation that PVL S. aureus strains produce PVL at concentra-
tions that will likely induce a host inflammatory response in the
infected tissue during human infection (1).
Are some genetic backgrounds of PVL strains higher-level
producers of PVL in vivo, as observed in vitro (16)? Focusing
on skin infections, we did not find an association between
specific genetic backgrounds and PVL concentrations. Fur-
thermore, PVL concentrations were not dependent on the
presence or the absence of mecA within the genetic back-
grounds. In addition, the PVL concentrations from specimen-
isolate pairs did not correlate; one could produce high levels of
PVL, while the other produced only small amounts. It is prob-
able that factors such as the type and extent of the infection,
the body site, and patient immunity factors influence the level
of PVL produced during the course of infection (8). Specimen
deterioration due to transportation may also have confounded
our results. A reliable comparison of the in vitro and in vivo
findings would entail quantitative cultures of specimens and
correlation to the number of bacteria present. That was not
attempted in this study. The difficulty in correlating the two
entities was previously discussed by Hamilton et al. (16).
Epidemiological data from different groups suggest that
PVL S. aureus strains are associated with some of the severe
forms of skin infection (9, 19, 24, 32), bone and joint infections
(4, 11), and pneumonia (14, 15). For these infections, experi-
mental data support the role of PVL in the severity of disease
(5, 6, 10, 28). The early diagnosis of PVL-positive S. aureus
infections by these immunological methods will allow physi-
cians to rapidly identify PVL-associated diseases. This might
become important if subsequent studies demonstrate that the
inhibition of PVL production and action results in improved
clinical outcomes (12, 15, 17).
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